Week 5: Challenges to Challenging the Status Quo in Psychedelic Research and Treatment

  • As a burgeoning treatment modality, psychedelic assisted therapy is often discussed as an alternative and challenge to the predominant psychotherapy modality of weekly 45-60 minute sessions. However, many aspects of psychedelic research and treatment are embedded in the same systems as other treatments.

  • This webinar will highlight and elucidate some of the challenges of navigating systems such as embedded economic interests and structures, intellectual property issues around patents and treatments, and difficulties in community outreach and training of culturally informed care.

Pricing options

Webinar Series Description

Live-Online Webinar Series Starting September 23rd.

  • Psychedelic-assisted therapy is making its way through the established medical system’s approval process and moving towards becoming an available treatment for conditions such as PTSD and Depression. This comes after years of prohibition of psychedelics through international drug conventions and local laws often disproportionately enforced in marginalized communities.

  • As states and regulatory bodies consider making psychedelic-assisted therapy available, key social justice considerations come into focus, particularly around healthcare disparities and access to treatment, the medicalization of plants that certain communities consider sacred, oppressive psychiatric treatments, and stigma experienced by people who use drugs.

  • The webinar series will cover a range of topics about both the present challenges and future opportunities for addressing social injustice in the field of psychedelic medicine, focusing on the role of the clinician’s voice in context of the larger healthcare system. The instructors and panelists will contribute their own unique perspectives and insights into the social justice implications of psychedelic-assisted therapy, research, and treatment.

  • Throughout the series participants will be encouraged to bring curiosity and openness to their own experiences, with a focus on developing insight and understanding based therein. To encourage ongoing reflection and engagement with the material participants will be invited to complete various exercises to clarify their reaction to the material, what they have learned and how they desire to incorporate these insights into their lives going forward.

Learning Objectives for Week 5

  • Analyze Intersection between research, policy, corporatization of psychedelics and its impact.

Instructors

Assistant Trainer

Kelly Sykes, PhD

Kelly Sykes, PhD is a child forensic psychologist and maintains a private practice in Brooklyn, New York. She works primarily with court referred families as a custody evaluator, parenting or family coordinator, or therapeutic supervisor. She also provides expert consultation and testimony in matters that concern parent-child contact problems, child sexual abuse evaluations, trauma & parenting, and adoption & termination of parental rights. Her work is heavily influenced by psychoanalysis and attachment theory. Kelly’s interest in psychedelic integration therapy evolved from years of working with court-referred parents with histories of complex trauma, persistent mood disorders, and substance abuse problems. Noting that for some, talk therapies helped with insight but failed to inhibit endangering behavior or led to meaningful change such that they could parent their children. This sparked her interest in learning more about the role the brain plays in the chronicity of certain psychological conditions and the research on psychedelic treatments.

Assistant Trainer

Alexander Camargo, Psy.D

Dr. Alex Camargo is a psychologist based in New York City and maintains a private practice in Manhattan. His work is heavily influenced by psychoanalytic and attachment theories where he works with clients to address anxiety, depression, life transitions and spiritual crises. In addition, he provides psychedelic harm reduction and integration, helping clients prepare for psychedelic experiences, incorporate insights or cope with challenges post-experience. He has also been employed to be a study therapist on a clinical trial investigating the impact of psilocybin on the treatment of body dysmorphic disorder at New York Psychiatric Institute. Dr. Camargo’s clinical training focused on providing mental health services in low-fee clinics and hospitals to traditionally underserved communities the Bronx, Brooklyn, and Nassau County.

Lead Trainer

Elizabeth Nielson, PhD

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.